Quick Answer
Coya Therapeutics, Inc. reported Net Income Loss of -$21.23 million for the year ending 2025.
- Coya Therapeutics, Inc. showed a decrease of -42.6% in Net Income Loss from 2024 to 2025.
- This data is from Coya Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2022: -$1.70 million | Q2 2022: -$3.41 million | Q3 2022: -$4.02 million | Q1 2023: -$2.74 million | Q2 2023: -$3.10 million | Q3 2023: -$3.42 million | Q1 2024: -$5.05 million | Q2 2024: -$2.89 million | Q3 2024: -$4.02 million | Q1 2025: -$7.31 million | Q2 2025: -$6.09 million | Q3 2025: -$2.12 million.
- Over the full 5 years of available data (2021 to 2025), Coya Therapeutics, Inc.'s Net Income Loss has declined by 333.9%.
- Historical annual values: Fiscal year 2025: -$21.23 million | Fiscal year 2024: -$14.88 million | Fiscal year 2023: -$7.99 million | Fiscal year 2022: -$12.24 million | Fiscal year 2021: -$4.89 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: